Navigation Links
Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
Date:11/7/2011

BASKING RIDGE, N.J., Nov. 7, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced the presentation of two posters highlighting positive substudy results of the Company's Phase 2b RADAR trial of REG1, Regado's proprietary anticoagulation system.  The posters will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium meeting on November 8, 2011 from 8:00-10:00 a.m. PST in San Francisco, CA.  

"The Phase 2b RADAR trial for REG1 has demonstrated a paradigm shift to provide physicians with a more effective option to control bleeding and ischemic events in ACS patients.  REG1 provides physicians the ability to titrate the intensity of anticoagulation according to specific patient needs, which are not currently met with existing drugs," said Dr. Mauricio Cohen, director of the cardiac catheterization laboratory at the University of Miami Miller School of Medicine and a lead investigator of the study, who will present the data.  "We're delighted to have the opportunity to share further analyses of these groundbreaking results among our peers."

The posters are titled "Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2b RADAR Trial" and "Access and non-Access Site Bleeding in Acute Coronary Syndrome Patients Treated with a Novel Actively Reversible Factor IXa Inhibitor: Results from the RADAR Trial."

REG1 is a two-component system consisting of pegnivacogin (a.k.a. RB006), a direct Factor IXa inhibitor, and anivamersen (a.k.a. RB007), its complementary active control agent.  The RADAR clinical trial demonstrated that REG1 provided nearly complete Factor IXa inhibition followed by 75% and 100% reversal, resulting in numerically lower rates of ischemic events when compared with heparin.  The res
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
2. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
3. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
5. Regado Biosciences Establishes Medical Advisory Board
6. Regado Biosciences Expands Medical Advisory Board
7. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
8. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
9. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
10. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
11. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... MDV-Mohr Davidow Ventures, a,leading Silicon Valley venture capital ... Dan Riskin to the firm as Executive-in-Residence and,Entrepreneur-in-Residence, ... provide healthcare providers and consumers more effective,ways to ... diagnosis to the,treatment of disease. , ...
... Switzerland and BANGALORE, India, November 20 ... development,specialist that focuses on serious medical ... Technologies Ltd (Aurigene), a,Bangalore-based fully integrated, ... peptide drug discovery and development from ...
... Nov. 19 Serica Technologies, Inc., a,growth-stage ... tissue regeneration, today announced that it has ... standards,required for medical device manufacturers. ISO certification ... regulatory bodies worldwide as proof of an,effective ...
Cached Biology Technology:MDV Expands Team Pursuing Advances in Personalized Medicine 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 2Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 4
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
(Date:4/15/2014)... New Zealand,s pastoral landscapes are some of the loveliest ... threat. Many of the country,s pasture soils have become ... metal, which is then eaten by the cattle and ... to New Zealand; cadmium-enriched soils being reported worldwide. , ... unsafe levels in meat and dairy products, human health ...
(Date:4/15/2014)... 2050, deforestation could cause temperatures in the Congo ... would intensify warming caused by greenhouse gases by ... the University of Leuven, Belgium. , Explosive population ... destruction of tropical rainforests in Central Africa. A ... examined how these practices will affect longer-term temperatures ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... 2011) Researchers looking to find a root cause for ... a novel investigative approach that borders on science fiction as ... the nation,s No. 1 killer. The National Institutes of ... Scripps Translational Science Institute (STSI) of San Diego and Sangamo ...
... wide variety of new cut flower cultivars and species ... University and the Association of Specialty Cut Flower Growers. ... United States and Canada, provides valuable production and marketing ... team from North Carolina State University undertook a multiyear ...
... Stephane Len, both researchers at the IRMES (Institut de ... France), have published their findings in Age , ... the evolution of performances in elite athletes and chess ... developed by the laboratory, and suggests that changes in ...
Cached Biology News:Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 2Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 3Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 4Extending the vase life of cut flowers: Pre-treatments and preservatives studied 2Evolution of sport performances follows a physiological law 2
... able to handle larger sample volumes, automate infusions, ... interface with telemetry systems. The AccuSampler LA ... pigs, and primates. The system may be ... computer can be located outside the animal room ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... key to successful cell culture or fermentation ... during the process, and make rapid adjustments ... Nova BioProfile Chemistry Analyzers provide immediate analysis ... cell culture and fermentation media. BioProfile analyzers ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
Biology Products: